RT @carpe_diem0820: グラム陰性菌のペニシリン結合タンパク質のジアザビシクロオクタン阻害剤を合理的に設計し、β-ラクタマーゼ酵素、ストリンジェント反応、外膜透過などの複数の耐性メカニズムを克服する戦略の概要 Rational design of a new…
RT @zenbrainest: "These attributes, along with a favourable preclinical safety profile, hold promise for the successful clinical developmen…
RT @Nature: A Nature paper reports on the development of a new class of antibiotic based on broad inhibition of penicillin-binding proteins…
My next read... Looks fabulous! I wonder if it's already or about to be in clinical trials
“Rational design of a new antibiotic class for drug-resistant infections” Durand-Reville, et al. https://t.co/I9D9he73zp
RT @utokawa: Rational design of a new antibiotic class for drug-resistant infections https://t.co/5gLBrkUJfx
RT @Nature: A Nature paper reports on the development of a new class of antibiotic based on broad inhibition of penicillin-binding proteins…
RT @Nature: A Nature paper reports on the development of a new class of antibiotic based on broad inhibition of penicillin-binding proteins…
RT @Nature: A Nature paper reports on the development of a new class of antibiotic based on broad inhibition of penicillin-binding proteins…
RT @CascalesLab: ETX0462, a diazabicyclooctane inhibitor of penicillin-binding proteins with enhanced capabilities, represents the first ne…
RT @carpe_diem0820: グラム陰性菌のペニシリン結合タンパク質のジアザビシクロオクタン阻害剤を合理的に設計し、β-ラクタマーゼ酵素、ストリンジェント反応、外膜透過などの複数の耐性メカニズムを克服する戦略の概要 Rational design of a new…
グラム陰性菌のペニシリン結合タンパク質のジアザビシクロオクタン阻害剤を合理的に設計し、β-ラクタマーゼ酵素、ストリンジェント反応、外膜透過などの複数の耐性メカニズムを克服する戦略の概要 Rational design of a new antibiotic class for drug-resistant infections https://t.co/1asjySIAdl https://t.co/XIKOC7ZCRK
New class of antib iotic, new hope!
RT @Nature: A Nature paper reports on the development of a new class of antibiotic based on broad inhibition of penicillin-binding proteins…
@tnatw
RT @Nature: A Nature paper reports on the development of a new class of antibiotic based on broad inhibition of penicillin-binding proteins…
RT @Nature: A Nature paper reports on the development of a new class of antibiotic based on broad inhibition of penicillin-binding proteins…
RT @hlcao: Rational design of a new antibiotic class for drug-resistant infections | Nature https://t.co/Lb4hMWNn6A
RT @Nature: A Nature paper reports on the development of a new class of antibiotic based on broad inhibition of penicillin-binding proteins…
Can’t wait ! !
RT @Nature: A Nature paper reports on the development of a new class of antibiotic based on broad inhibition of penicillin-binding proteins…
RT @Nature: A Nature paper reports on the development of a new class of antibiotic based on broad inhibition of penicillin-binding proteins…
RT @ravboc: A new class of antibiotics: Rational design of diazabicyclooctane inhibitors of penicillin-binding proteins from Gram-negative…
RT @Nature: A Nature paper reports on the development of a new class of antibiotic based on broad inhibition of penicillin-binding proteins…
RT @Nature: A Nature paper reports on the development of a new class of antibiotic based on broad inhibition of penicillin-binding proteins…
RT @Nature: A Nature paper reports on the development of a new class of antibiotic based on broad inhibition of penicillin-binding proteins…
A Nature paper reports on the development of a new class of antibiotic based on broad inhibition of penicillin-binding proteins from Gram-negative bacteria. https://t.co/ycLdTMsX3q https://t.co/HmgoQx8rxW
RT @OdedRechavi: “These attributes, along with a favourable preclinical safety profile, hold promise for the successful clinical developmen…
×SAM-e?
×Phosphopyricin??
RT @ravboc: A new class of antibiotics: Rational design of diazabicyclooctane inhibitors of penicillin-binding proteins from Gram-negative…
RT @LauraPiddock: Rational design of a new antibiotic class for drug-resistant infections | Nature https://t.co/QwmwXrlEgx
RT @CascalesLab: ETX0462, a diazabicyclooctane inhibitor of penicillin-binding proteins with enhanced capabilities, represents the first ne…
RT @Entasistx: We are excited to announce the publication of a profile of the company’s ETX0462 candidate in the prestigious scientific jou…
Haven’t came across such a great science for a long time! Totally awestruck with the manuscript of @RTommasi27 & team! It’s a gran negative single agent antibiotic!
RT @Entasistx: We are excited to announce the publication of a profile of the company’s ETX0462 candidate in the prestigious scientific jou…
RT @CascalesLab: ETX0462, a diazabicyclooctane inhibitor of penicillin-binding proteins with enhanced capabilities, represents the first ne…
RT @LauraPiddock: Rational design of a new antibiotic class for drug-resistant infections | Nature https://t.co/QwmwXrlEgx
resisting resistance 💊🤜🧫
RT @CascalesLab: ETX0462, a diazabicyclooctane inhibitor of penicillin-binding proteins with enhanced capabilities, represents the first ne…
RT @RTommasi27: Check out our new paper in Nature. If fully developed, ETX0462 represents the first novel class of Gram-negative single age…
$ETTX Company is expected to release two Phase 3 results in early Q4. Great opportunity to own this stock at these low prices. Average analyst PT is $5.
This is the most hopeful thing you'll read today. Our battle against the post-antibiotic world continues.
Rational design of a new antibiotic class for drug-resistant infections ...hold promise for the successful clinical development of the first novel Gram-negative Abx to treat antibiotic-resistant infections in over 25 yrs https://t.co/o1szXhTxsi
Much needed! https://t.co/1yqH3DmrON
$ETTX Entasis pub in journal Nature. https://t.co/oI9DiibbS0
RT @OdedRechavi: “These attributes, along with a favourable preclinical safety profile, hold promise for the successful clinical developmen…
Rational design of a new antibiotic class for drug-resistant infections | Nature https://t.co/Lb4hMWNn6A
Indeed always great to see new drugs in the pipeline...https://t.co/GBV9Bn7tQo
Rational design of a new antibiotic class for drug-resistant infections https://t.co/u0rX0fQwqp @nature
From what I’ve seen on service, GN aren’t taking a backseat to covid kindly. Some really nasty combo porin/enzyme/pump Pseudos out there. Hope it makes it to clinical use! https://t.co/heTjkSlTZP
Congratulations Ruben and @Entasistx team!
RT @CascalesLab: ETX0462, a diazabicyclooctane inhibitor of penicillin-binding proteins with enhanced capabilities, represents the first ne…
For 25 years, until today, we had no novel antibiotic drug class against Gram-negative bacteria. Well done.
RT @ravboc: A new class of antibiotics: Rational design of diazabicyclooctane inhibitors of penicillin-binding proteins from Gram-negative…
Great paper by the group of @RTommasi27 @Entasistx in @Nature. The diazabicyclooctane ETX0462 is a new antibiotic for Gram-negative bacteria, inhibits PBP1a and PBP3, is resistant to β-lactamases, has a low frequency of resistance, high porin uptake and hi
A new class of antibiotics: Rational design of diazabicyclooctane inhibitors of penicillin-binding proteins from Gram-negative bacteria to overcome multiple mechanisms of resistance, including β-lactamase enzymes, stringent response and outer membrane perm
Rational design of a new antibiotic class for drugresistant infections null https://t.co/nV74P16rA7 #DTHSTR
👇👇👇 THIS! THIS! THIS! 👇👇👇
A news to celebrate! Congratulations @RTommasi27 and the Team!
RT @koutterson: Congratulations on this paper in Nature on ETX0462, which was also supported by @CARB_X
RT @koutterson: Congratulations on this paper in Nature on ETX0462, which was also supported by @CARB_X
RT @koutterson: Congratulations on this paper in Nature on ETX0462, which was also supported by @CARB_X
RT @OdedRechavi: “These attributes, along with a favourable preclinical safety profile, hold promise for the successful clinical developmen…
RT @koutterson: Congratulations on this paper in Nature on ETX0462, which was also supported by @CARB_X
Intriguing
Very important
Rational design of a new antibiotic class for drug-resistant infections | Nature https://t.co/QwmwXrlEgx
One of the most exciting drug development related manuscripts lately: Rational design of a new antibiotic class for drug-resistant infections | Naturel https://t.co/dScofvjSdx
RT @OdedRechavi: “These attributes, along with a favourable preclinical safety profile, hold promise for the successful clinical developmen…
“These attributes, along with a favourable preclinical safety profile, hold promise for the successful clinical development of the first novel Gram-negative chemotype to treat life-threatening antibiotic-resistant infections in more than 25 years.”
RT @CascalesLab: ETX0462, a diazabicyclooctane inhibitor of penicillin-binding proteins with enhanced capabilities, represents the first ne…
RT @houndcl: Interesting prodrug and a new class of diazabicyclooctane antibiotics ETX0462. PDB: 7JWL https://t.co/g5eTrEA68Y
RT @RTommasi27: Check out our new paper in Nature. If fully developed, ETX0462 represents the first novel class of Gram-negative single age…
RT @RTommasi27: Check out our new paper in Nature. If fully developed, ETX0462 represents the first novel class of Gram-negative single age…
New antibiotic class? https://t.co/GHjRsBbjk2
RT @RTommasi27: Check out our new paper in Nature. If fully developed, ETX0462 represents the first novel class of Gram-negative single age…
Interesting prodrug and a new class of diazabicyclooctane antibiotics ETX0462. PDB: 7JWL https://t.co/g5eTrEA68Y
RT @CARB_X: We're thrilled to see this terrific paper published in @Nature! Congratulations @Entasistx! @BARDA @Wellcome_AMR @NIAIDNews @U…
RT @CascalesLab: ETX0462, a diazabicyclooctane inhibitor of penicillin-binding proteins with enhanced capabilities, represents the first ne…
RT @CARB_X: We're thrilled to see this terrific paper published in @Nature! Congratulations @Entasistx! @BARDA @Wellcome_AMR @NIAIDNews @U…
This brilliant news. Hopefully the drug can be developed.
RT @CascalesLab: ETX0462, a diazabicyclooctane inhibitor of penicillin-binding proteins with enhanced capabilities, represents the first ne…
We are excited to announce the publication of a profile of the company’s ETX0462 candidate in the prestigious scientific journal Nature. Check out the article below: https://t.co/hamQTs89pl
RT @CascalesLab: ETX0462, a diazabicyclooctane inhibitor of penicillin-binding proteins with enhanced capabilities, represents the first ne…
Exciting development in antibiotic drug discovery
That is quite an achievement.
ETX0462, a diazabicyclooctane inhibitor of penicillin-binding proteins with enhanced capabilities, represents the first new class of antibiotics active against Gram negative for the last 25 years ! @Nature #Antibiotics #AMR https://t.co/q9RiQkaoQe
Awesome stuff for those who care about #AMR.
RT @koutterson: Congratulations on this paper in Nature on ETX0462, which was also supported by @CARB_X
RT @CARB_X: We're thrilled to see this terrific paper published in @Nature! Congratulations @Entasistx! @BARDA @Wellcome_AMR @NIAIDNews @U…
RT @CARB_X: We're thrilled to see this terrific paper published in @Nature! Congratulations @Entasistx! @BARDA @Wellcome_AMR @NIAIDNews @U…
We're thrilled to see this terrific paper published in @Nature! Congratulations @Entasistx! @BARDA @Wellcome_AMR @NIAIDNews @UKgovGHS @BMBF_Bund @gatesfoundation
Congratulations on this paper in Nature on ETX0462, which was also supported by @CARB_X
RT @zenbrainest: "These attributes, along with a favourable preclinical safety profile, hold promise for the successful clinical developmen…
Rational design of a new antibiotic class for drug-resistant infections https://t.co/14m7uepnHZ
Rational design of a new antibiotic class for drug-resistant infections https://t.co/1GRwBaQSkw https://t.co/MtmhdHk35v | #research #manuscripts @nature
Rational design of a new antibiotic class for drug-resistant infections https://t.co/AmjBP4zhUm
"These attributes, along with a favourable preclinical safety profile, hold promise for the successful clinical development of the first novel Gram-negative chemotype to treat life-threatening antibiotic-resistant infections in more than 25 years." https:/